Profile data is unavailable for this security.
About the company
Aarti Drugs Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals includes benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
- Revenue in INR (TTM)24.23bn
- Net income in INR1.57bn
- Incorporated1984
- Employees1.06k
- LocationAarti Drugs LtdMahendra Industrial Estate,Ground Floor, Road No 29, Plot No 109-D,MUMBAI 400022IndiaIND
- Phone+91 2 224019025
- Fax+91 2 224073462
- Websitehttps://www.aartidrugs.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 28.85bn | 1.13k | -- | -- | 167.04 | 1.19 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| SMS Pharmaceuticals Ltd | 7.38bn | 569.64m | 29.32bn | 1.20k | 51.31 | -- | 32.95 | 3.97 | 6.75 | 6.75 | 87.48 | -- | -- | -- | -- | 6,168,549.00 | -- | 5.43 | -- | 7.33 | 30.12 | 33.30 | 7.69 | 7.87 | -- | 4.21 | -- | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Indoco Remedies Ltd | 18.22bn | 766.90m | 31.38bn | 5.93k | 41.28 | -- | 18.02 | 1.72 | 8.25 | 8.25 | 178.33 | -- | -- | -- | -- | 3,072,462.00 | -- | 6.88 | -- | 9.85 | 68.61 | 65.59 | 4.10 | 6.93 | -- | 2.95 | -- | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Solara Active Pharma Sciences Ltd | 13.00bn | -5.61bn | 31.83bn | 2.16k | -- | -- | -- | 2.45 | -143.75 | -143.75 | 334.17 | -- | -- | -- | -- | 6,030,149.00 | -- | -2.44 | -- | -3.84 | 37.34 | 41.16 | -43.17 | -4.49 | -- | -1.57 | -- | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 39.15bn | 1.23k | -- | 123.84 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 39.36bn | 1.45k | 45.13 | -- | 38.04 | 4.83 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Innova Captab Ltd | 11.42bn | 1.06bn | 41.36bn | -- | 30.51 | -- | 33.29 | 3.62 | 23.69 | 23.69 | 236.62 | -- | -- | -- | -- | -- | -- | 10.82 | -- | 18.38 | 33.38 | 25.18 | 9.30 | 8.04 | -- | 8.89 | -- | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Hikal Ltd | 18.03bn | 677.82m | 41.87bn | 2.06k | 61.80 | -- | 22.10 | 2.32 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 45.74bn | 1.27k | 49.54 | -- | 41.41 | 7.63 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Aarti Drugs Ltd | 24.23bn | 1.57bn | 46.55bn | 1.06k | 29.86 | -- | 22.26 | 1.92 | 17.08 | 17.08 | 263.82 | -- | -- | -- | -- | 22,770,740.00 | -- | 9.73 | -- | 15.78 | 34.32 | 22.23 | 6.48 | 8.25 | -- | 7.28 | -- | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Unichem Laboratories Ltd | 17.28bn | -605.50m | 47.11bn | 3.19k | -- | -- | 90.17 | 2.73 | -8.59 | -8.59 | 245.15 | -- | -- | -- | -- | 5,410,587.00 | -- | -1.67 | -- | -2.03 | 62.00 | 56.18 | -3.50 | -3.99 | -- | 0.1401 | -- | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Supriya Lifescience Ltd | 5.99bn | 1.35bn | 47.18bn | 448.00 | 34.90 | -- | 31.09 | 7.88 | 16.80 | 16.80 | 74.42 | -- | -- | -- | -- | 13,370,000.00 | -- | 19.08 | -- | 24.04 | 62.75 | 57.12 | 22.58 | 24.71 | -- | 92.47 | -- | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 48.19bn | 1.20k | 905.27 | -- | 62.04 | 3.38 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 48.74bn | 1.62k | 38.49 | -- | 32.57 | 2.79 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Aarti Pharmalabs Ltd | 19.50bn | 2.25bn | 55.29bn | 1.63k | 24.54 | -- | 18.34 | 2.84 | 24.86 | 24.86 | 215.17 | -- | -- | -- | -- | 11,983,730.00 | -- | -- | -- | -- | 44.20 | -- | 11.55 | -- | -- | 18.55 | -- | -- | -4.76 | -- | 12.10 | -- | -- | -- |
Data as of Oct 11 2024. Currency figures normalised to Aarti Drugs Ltd's reporting currency: Indian Rupee INR
6.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 30 Jun 2024 | 5.19m | 5.64% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 514.81k | 0.56% |
| Mellon Investments Corp.as of 03 Jul 2024 | 250.64k | 0.27% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 104.03k | 0.11% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 93.69k | 0.10% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jul 2024 | 61.71k | 0.07% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 52.72k | 0.06% |
| TIAA-CREF Investment Management LLCas of 30 Jun 2024 | 33.65k | 0.04% |
| State Street Global Advisors Ltd.as of 04 Jul 2024 | 32.61k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 21.47k | 0.02% |
More ▼
Data from 31 Mar 2024 - 08 Aug 2024Source: FactSet Research Systems Inc.
